前往化源商城

喹普利拉

更新时间:2025-08-20 17:59:58

喹普利拉结构式
喹普利拉结构式
品牌特惠专场
常用名 喹普利拉 英文名 CI928
CAS号 82768-85-2 分子量 410.46300
密度 1.289 g/cm3 沸点 674.5ºC at 760 mmHg
分子式 C23H26N2O5 熔点 166-168ºC
MSDS 中文版 美版 闪点 361.7ºC

 喹普利拉用途


奎那普利是一种口服活性非巯基血管紧张素转换酶(ACE)抑制剂,是奎那普利的活性代谢物。奎那普利特异性阻断血管紧张素I向血管收缩剂血管紧张素II的转化,并抑制缓激肽的降解。奎那普利特作为抗高血压药和血管扩张剂[1][2]。

 喹普利拉名称

中文名 喹普利拉
英文名 quinaprilat hydrate
英文别名 更多

 喹普利拉生物活性

描述 奎那普利是一种口服活性非巯基血管紧张素转换酶(ACE)抑制剂,是奎那普利的活性代谢物。奎那普利特异性阻断血管紧张素I向血管收缩剂血管紧张素II的转化,并抑制缓激肽的降解。奎那普利特作为抗高血压药和血管扩张剂[1][2]。
相关类别
体外研究 奎那普利(5μM)介导有机阴离子转运体3(hOAT3)的相互作用,该转运体可促进奎那普利的肾脏活性分泌,使HEK293细胞对奎那普利特的摄取增加到25倍,且hOAT3对奎那普里特的亲和力Km为13.4μM[1]。奎那普利(100nM,20min)可通过激活B1受体抑制蛋白激酶C(PKC)的活性,导致人肺微血管内皮(HLMVE)细胞释放NO[2]。
参考文献

[1]. Haodan Yuan, et al. Renal organic anion transporter-mediated drug-drug interaction between gemcabene and quinapril. J Pharmacol Exp Ther. 2009 Jul;330(1):191-7. doi: 10.1124/jpet.108.149476. Epub 2009 Apr 6.

[2]. Sinisa Stanisavljevic, et al. Angiotensin I-converting enzyme inhibitors block protein kinase C epsilon by activating bradykinin B1 receptors in human endothelial cells. J Pharmacol Exp Ther. 2006 Mar;316(3):1153-8.

 喹普利拉物理化学性质

密度 1.289 g/cm3
沸点 674.5ºC at 760 mmHg
熔点 166-168ºC
分子式 C23H26N2O5
分子量 410.46300
闪点 361.7ºC
精确质量 410.18400
PSA 106.94000
LogP 2.41740
外观性状 结晶固体

 喹普利拉MSDS

 喹普利拉毒性和生态

 喹普利拉安全信息

危险品运输编码 NONH for all modes of transport

 喹普利拉上下游产品

喹普利拉上游产品  3

喹普利拉下游产品  0

 喹普利拉文献23

更多文献
Haemodynamic effects of intravenous quinaprilat in comparison to sodium nitroprusside in patients with chronic heart failure.

Int. J. Cardiol. 121(1) , 102-4, (2007)

We compared the haemodynamic effects of intravenous boluses of the ACE inhibitor quinaprilat with an intravenous infusion of sodium nitroprusside in 23 patients with chronic heart failure (NYHA Class ...

Quinaprilat reduces myocardial infarct size involving nitric oxide production and mitochondrial KATP channel in rabbits.

J. Cardiovasc. Pharmacol. 41(6) , 938-45, (2003)

This study examined whether quinaprilat, an angiotensin-converting enzyme inhibitor, reduces the infarct size, and investigated the mechanisms for its infarct size-reducing effect, in rabbits. Japanes...

LC-MS/MS assay of quinapril and its metabolite quinaprilat for drug bioequivalence evaluation: prospective, concurrential and retrospective method validation.

Bioanalysis 1(1) , 71-86, (2009)

The bioequivalence of two pharmaceutical formulations containing 10 mg quinapril was assessed by assaying the untransformed drug and its active metabolite quinaprilat from plasma samples.A gradient el...

 喹普利拉英文别名

(3S)-2-[(S)-2-[[(S)-1-Carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
quinapril diacid
ci928
(3s-(2(r*(r*)),3r*))-yl)amino)-1-oxopropyl)
(3S)-2-[(S)-2-[[(S)-1-Carboxy-3-phenylpropyl]amino]propionyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
[3S-[2[R*(R*)],3R*]]-2[2-[[1-(carboxy)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid
CI-92
3-Isoquinolinecarboxylic acid,2-(2S)-2-(1S)-1-carboxy-3-phenylpropylamino-1-oxopropyl-1,2,3,4-tetrahydro-,(3S)
3-isoquinolinecarboxylicacid,1,2,3,4-tetrahydro-2-(2-((1-carboxy-3-phenylprop
quinaprilate
(3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic Acid
本网页内容来自不同专业数据源,如对内容有疑义,欢迎联系service1@chemsrc.com。
品牌现货直购
推荐供应商:

查看所有供应商和价格请点击:

喹普利拉生产厂家

喹普利拉价格